Brief: Ultimovacs Says Uv1 In Combination With Pembrolizumab Shows 60% Objective
19/05/2021 21:54
May 19 (Reuters) - Ultimovacs ASA ULTIMO.OL :
* ULTIMOVACS' UV1 IN COMBINATION WITH PEMBROLIZUMAB SHOWS
60%
OBJECTIVE
* UV1/PEMBROLIZUMAB RESULTS IN 30% COMPLETE RESPONSES PLUS
30%
PARTIAL RESPONSES
* ULTIMOVACS - GOOD SAFETY AND TOLERABILITY PROFILE SUPPORTS
USE
OF UV1 IN COMBINATION TREATMENTS
Source text for Eikon: ID:nObiwxwKya
Further company coverage: ULTIMO.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant